FDA OKs Sparsentan for Rare Kidney Disease

The US FDA gave accelerated approval to sparsentan as the first non-immunosuppressive therapy labeled for IgA nephropathy. Conventional approval awaits clinical outcomes data.
FDA Approvals

source https://www.medscape.com/viewarticle/988482?src=rss